ARA-290 (Cibinetide) RA
Innate repair receptor agonist
Cibinetide, an 11-amino-acid peptide designed from erythropoietin, that interacts selectively with the innate repair receptor.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- Innate repair receptor agonist
- Category
- Tissue Repair & Recovery
- Type
- Single compound
- Abbreviation
- RA
- Development and regulatory status
- Investigational; completed phase 2 trials; not approved
What researchers study
ARA-290 (cibinetide) is an 11-amino-acid peptide designed from the structure of erythropoietin. It interacts selectively with the innate repair receptor and does not stimulate red-blood-cell production.
Research areas
- Small-fibre neuropathy and corneal nerve imaging studies
- Inflammation and tissue-protection signalling
- Metabolic-control endpoints in diabetes trials
- Innate repair receptor pharmacology
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- phase 2 trial
In 64 people with sarcoidosis-related small nerve fibre loss, one treatment group showed greater corneal nerve fibre area than placebo (P = 0.012)
- phase 2 trial
In type 2 diabetes with painful neuropathy, HbA1c, lipid profiles and PainDetect symptom scores improved in the treated group
- phase 2 trial
In a 9-participant diabetic macular oedema study, visual acuity and retinal thickness did not improve, and no serious adverse events occurred
Studied alongside
Compounds that appear together in research because their mechanisms complement each other, or as comparators. The reasons given are research reasoning, not recommendations for use.
- BPC-157Different cytoprotective pathway studied in tissue-injury and angiogenesis models
- TB-500 (Thymosin Beta-4 Acetate)Cell-migration repair peptide acting through a different pathway
